Tengion
Tengion is a biotechnology company that specializes in the development of regenerative medicine therapies. The company's primary focus is on the creation of functional, bioengineered organs and tissues for transplantation. Tengion's approach involves using a patient's own cells to create new organs or tissues, which can then be transplanted back into the patient. This approach is designed to avoid the problems associated with organ rejection and the need for lifelong immunosuppressive therapy.
History[edit | edit source]
Tengion was founded in 2003 by Dr. Anthony Atala, a pioneer in the field of regenerative medicine. The company was initially based in Winston-Salem, North Carolina, but later moved its headquarters to East Norriton, Pennsylvania. Tengion has been involved in several significant research and development projects, including the creation of a bioengineered bladder and the development of a neo-kidney augment.
Research and Development[edit | edit source]
Tengion's research and development efforts are focused on the creation of bioengineered organs and tissues. The company's primary product is the Neo-Bladder, a bioengineered bladder that is created using a patient's own cells. The Neo-Bladder is designed to replace a patient's existing bladder in cases where the bladder has been damaged or removed due to disease or injury.
In addition to the Neo-Bladder, Tengion is also developing a product known as the Neo-Kidney Augment. This product is designed to delay or prevent the need for dialysis or kidney transplantation in patients with chronic kidney disease.
Clinical Trials[edit | edit source]
Tengion has conducted several clinical trials to test the safety and efficacy of its products. The company's Neo-Bladder has been tested in a Phase I clinical trial, and the results of this trial have been published in the medical journal The Lancet. The Neo-Kidney Augment is currently in the preclinical stage of development.
Financial Information[edit | edit source]
Tengion is a privately held company, and its financial information is not publicly available. The company has received funding from a variety of sources, including venture capital firms and government grants.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
